# Aimovig Pregnancy Exposure Registry

> **NCT06150781** · — · RECRUITING · sponsor: **Amgen** · enrollment: 2842 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** erenumab-aooe

## Key facts

- **NCT ID:** NCT06150781
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-27
- **Primary completion:** 2027-10-28
- **Final completion:** 2027-10-28
- **Target enrollment:** 2842 (ESTIMATED)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150781, "Aimovig Pregnancy Exposure Registry". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06150781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*